Direct Impact

Concepts for which Alexey Danilov MD has direct influence:

lymphocytic lymphoma
refractory chronic
entospletinib obinutuzumab
leukemia small
response phase

Prominent publications by Alexey Danilov, MD

KOL-Index: 2 This phase I/II trial studies the side effect and best dose of entospletinib when giving together with obinutuzumab and to see how well they work in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma that has come back. Entospletinib may stop the growth of cancer cells by blocking some of the enzymes need for cell growth. Monoclonal ...
Known for
Sll Hodgkin | Phase Event | Cycles Entospletinib | Cll Cells

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172